Steve Bryson, PhD,  science writer—

Altavant Sciences has opened ELEVATE 2, its global Phase 2b clinical trial into the safety and efficacy of rodatristat ethyl, a potential disease-modifying oral therapy for people with pulmonary arterial hypertension (PAH). The…

Iron replacement did not affect disease severity or the ability to function in people with pulmonary arterial hypertension (PAH), an analysis of two clinical studies showed.  It also was found to have no impact on quality of life for these patients.

Diminazene aceturate (DIZE), an approved antiparasitic medication, lessened the development of pulmonary arterial hypertension (PAH) in a rat model, a study has demonstrated. These findings support further investigation of DIZE as a potential treatment for PAH, scientists said.  The…

Adipose (fat) tissue may contribute to the development of pulmonary arterial hypertension (PAH) due to certain metabolic alterations found, for the first time, in patients and also in rodent models of the condition, a study suggests. The study, “…

A gene called DNMT3B was found for the first time to be a mediator of blood vessel wall growth, and has been implicated in the development of pulmonary hypertension (PH) in a rat study. This gene, which regulates inflammatory pathways…

Elevated blood levels of the kidney disease biomarker creatinine and the heart failure biomarker NT-proBNP were found to be independent predictors of mortality for older people with pulmonary arterial hypertension (PAH) who were born with congenital heart disease…

People with both pulmonary hypertension (PH) and interstitial lung disease (ILD) have worse survival outcomes than ILD patients who don’t have PH, a study has found.  Lung function and blood flow tests were important predictors of overall survival in this patient population, according to the study, “…

An increase in right atrial blood pressure during exercise in people with pulmonary hypertension (PH) reflects problems with blood flow in the heart and is linked to a worse prognosis and higher mortality, a study shows. Researchers therefore suggest that right atrial blood…

Off-label use of prostacyclin therapy successfully treated five newborns with persistent pulmonary hypertension of the neonate (PPHN), and switching from intravenous infusion to subcutaneous injection was well tolerated, a case series reported.  Its authors recommend larger studies to…

New variants in the DNA region that promote the activity of the BMPR2 gene — associated with familial pulmonary arterial hypertension (PAH) — lower the gene’s activity and may contribute to the condition in some families, a study…

Elevated levels of the protein IGFBP2 were identified in the blood of people with pulmonary arterial hypertension (PAH) and found to be associated with lower physical function, higher arterial blood pressure, and an increased mortality risk, a study reports.  …

For the first time, the long-term use of antipsychotic medications has been linked to the development of chronic thromboembolic pulmonary hypertension (CTEPH), a case study reports.  The authors recommend that CTEPH should be considered in patients who receive antipsychotics and also have symptoms associated…